GPT and tuberculosis: There were four subjects with treatment emergent adverse events (TEAE’s) leading to withdrawal; one subject each in the delpazolid 400 mg BID and 1,200 mg QD groups experienced worsening TB that was considered unlikely related to the study drug and one subject in the HRZE was withdrawn due to increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) that was assessed as “probably related to the study drug.”